Sacituzumab Biosimilar - Research Grade

Human

TACSTD2

>1mg/ml

Human IgG1

Datopotamab Biosimilar - Research Grade (ICH5217)

https://www.imgt.org/mAb-DB/

ICH3002

P09758

Blue ice

ICH5076 is a research-grade, unconjugated recombinant analog of sacituzumab, a human IgG1 antibody directed against TACSTD2 (Trop-2). It is supplied as a non-therapeutic reagent for research use only and is not the clinical product; it is intended for laboratory and preclinical applications rather than human or veterinary use. Because it is built around the Trop-2 target and carries a human IgG1 framework, it is well suited to in-vitro binding characterization, epitope and cross-reactivity studies, flow cytometry of Trop-2-expressing cells, and as a targeting moiety in antibody-drug conjugate (ADC) development workflows where sacituzumab is the reference antibody. Being unconjugated, it also serves as a naked-antibody control against conjugated formats. The material is offered at low endotoxin (research grade typically <1 EU/mg, with ultra-low <0.5 EU/mg options) and in bulk milligram-to-gram quantities, supporting assay standardization, positive/negative controls, and preclinical model work. Investigators should validate lot performance in their own systems before use. TACSTD2 (tumor-associated calcium signal transducer 2), commonly called Trop-2, is a single-pass type I transmembrane glycoprotein encoded by an intronless gene. Its extracellular region contains a cysteine-rich domain and a thyroglobulin type-1 repeat, followed by a transmembrane segment and a short cytoplasmic tail bearing a PIP2-binding sequence and a conserved serine phosphorylation site. Trop-2 participates in intracellular calcium signaling and modulates proliferation, adhesion, and migration, in part through regulated intramembrane proteolysis that releases signaling fragments. It is expressed in many normal epithelia but is markedly overexpressed across numerous carcinomas, including triple-negative breast, urothelial, and lung cancers, where high expression often correlates with aggressive behavior. This tumor-associated overexpression and cell-surface accessibility make Trop-2 an attractive target for antibody-based and ADC therapeutics, and a useful antigen for research reagents.

Cell surface glycoprotein Trop-2, Membrane component chromosome 1 surface marker 1, Pancreatic carcinoma marker protein GA733-1, Tumor-associated calcium signal transducer 2, GA733-1, M1S1, TROP2

Detects human TACSTD2. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Sacituzumab.

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Q: Is the Sacituzumab biosimilar available in gram quantities?

A: Yes — it is supplied in scalable milligram to gram quantities for heavy-usage and high-throughput laboratories.

Q: Is this research-grade Sacituzumab suitable for in vivo studies?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Sacituzumab biosimilar target?

A: It is an unconjugated, non-therapeutic analog of Sacituzumab that binds human TACSTD2.